Beam Therapeutics (MEX:BEAM) Risk Assessment


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
69 GF Score
Price MXN655.00
GF Value MXN616.29
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Beam Therapeutics is: High Risk: High uncertainty with risk-return tradeoff.

Beam Therapeutics  (MEX:BEAM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Beam Therapeutics Risk Assessment Related Terms

MEX:BEAM vs ELVN, IDYA, PBLS: Risk Assessment Comparison

For the Biotechnology subindustry, Beam Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Risk Assessment falls into.


MEX:BEAM
69GF Score
Beam Therapeutics Inc MEX:BEAM
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 6.3% above its estimated GF Value™ of MXN616.29. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Risk Assessment:
  • GF Value™: MXN616.29 vs. price of MXN655.00 (6.3% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
69GF Score

Get the complete analysis for MEX:BEAM

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN616.29
GF Value